Two biotech names just gave investors stronger Phase 3 data in major cancer markets, while one chip-design software leader is pushing generative AI deeper into semiconductor development. The common thread is clear: real product progress, real market opportunity, and enough evidence to keep all three in the buy column.
Hidden Tax Breaks (Sponsored)
Capital gains taxes may quietly reduce more of your investment returns than you realize.
But the tax code includes several strategies that may help reduce that bill.
Three often-overlooked areas include investment-related expenses, cost basis adjustments, and real estate selling costs.
When structured correctly, these deductions may help minimize taxable gains.
Because the rules can be complex, many investors work with fiduciary financial advisors to plan tax-efficient strategies.
Futures at a Glance📈
Futures are moving higher as June kicks off with the market sitting near fresh records. The U.S.-Iran ceasefire extension is keeping risk appetite alive, though oil is bouncing after a rough May and traders are already looking ahead to Friday’s jobs report.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (Premarket):
• Science Applications International Corporation [SAIC]
Earnings (Aftermarket):
• Hewlett Packard Enterprise Company [HPE]
• Credo Technology Group Holding Ltd [CRDO]
• HIVE Digital Technologies Ltd [HIVE]
Earnings (Time Not Supplied):
• Woodside Energy Group Limited [WDS]
• Trip.com Group Limited [TCOM]
• Uranium Energy Corp. [UEC]
Economic Reports:
• S&P final U.S. manufacturing PMI (May): 9:45 am
• ISM manufacturing (May): 10:00 am
• Construction spending (April): 10:00 am
• Auto sales (May): TBA
Elite Trade Club Insider
Two CEOs Just Sold More Than $94 Million
One rare earths CEO sold more than $26.2 million after a 215% one-year run, while the CEO of a travel platform sold another $68.4 million near the stock’s upper range. You’re seeing two familiar growth stories. Insider readers are seeing where the people at the top are using strength to cash out while the market is still debating the next leg.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Biotech
Summit Therapeutics Just Raised the Stakes in the Keytruda Successor Race
Summit Therapeutics Inc (NASDAQ: SMMT) is getting a strong premarket move after new ASCO data strengthened the case for Ivonescimab as a potential challenger in the post-Keytruda cancer-drug race.
Shares rose more than 11% premarket after the company said its Phase 3 Harmoni-6 study showed a statistically significant survival advantage over a PD-1 inhibitor plus chemotherapy.
That matters because this is one of the biggest prizes in oncology. Merck’s Keytruda has dominated the immunotherapy market, and Big Pharma is already chasing the next wave of treatments.
Pfizer, Bristol Myers Squibb, and Merck are all working on rival therapies aimed at the same opportunity. If Ivonescimab can show survival benefit in a large Phase 3 setting, Summit moves from “promising biotech story” to a more serious competitive threat.
The stock still comes with biotech risk. Summit has a market cap above $13 billion, no P/E ratio, and a share price well below its 52-week high of $30.98. That means investors are still weighing the upside of a major oncology asset against the uncertainty of approvals, commercialization, and competitive response.
My Take For You: Summit now has stronger clinical proof behind its cancer-drug story, and that makes the stock more than a speculative ASCO trade.
My Verdict: Buy this. The risk is that regulators or follow-up data weaken the case before Ivonescimab can become a true Keytruda challenger.
Design Software
Cadence Design Systems Is Bringing Generative AI Deeper Into Chip Design
Cadence Design Systems Inc (NASDAQ: CDNS) is moving higher after unveiling what it calls the industry’s first fully autonomous virtual engineer for chip design, built with generative AI in partnership with NVIDIA. Investors are treating the launch as another sign that Cadence can stay central to the future of AI hardware development.
That position matters. Cadence sells electronic design automation tools that help companies design increasingly complex chips.
As AI chips become more advanced, the design process gets harder, more expensive, and more time-sensitive. A generative AI engineering assistant could make Cadence’s platform more valuable by helping customers move faster through design, testing, and optimization.
The company also received a sentiment boost from a new licensing deal with LiDAR maker Aeva, expanding its reach into advanced sensing technologies.
The stock is up about 28% over the past year, trades near a $103 billion market cap, and carries a high P/E near 88x. That valuation is demanding, but Cadence sits in a structurally important part of the semiconductor supply chain.
My Take For You: Cadence is not just riding the AI chip wave. It is building tools that could make the next generation of AI hardware easier to design.
My Verdict: Buy this. The risk is that the stock’s high multiple leaves it vulnerable if AI design automation adoption takes longer than expected.
What Filing Signals (Sponsored)
New Nevada court filing reveals Tesla may be next in line for an Elon Musk Mega Merger.
Last time Tesla merged well positioned investors saw 30X gains.
Don't miss out.
Legendary tech angel investor shares the details in this short briefing.
Biotech
Revolution Medicines Gets the Phase 3 Data Biotech Investors Wait For
Revolution Medicines Inc (NASDAQ: RVMD) gave investors a major clinical catalyst with positive Phase 3 data from its RASolute 302 trial.
The study tested daraxonrasib, an oral RAS-targeted therapy, in previously treated metastatic pancreatic ductal adenocarcinoma. The company said the trial met all primary and key secondary objectives, showing statistically significant and clinically relevant improvement versus chemotherapy.
That is a big deal because pancreatic cancer remains one of the hardest areas in oncology. New treatment options are limited, outcomes are poor, and RAS mutations have historically been difficult to target. If daraxonrasib can become a real option for these patients, Revolution’s platform gets a much stronger validation signal.
The market already knows the stock has a huge opportunity. Shares are up nearly 287% over the past year, and the company now carries a market cap above $33 billion.
That valuation leaves little room for clinical disappointment, especially with insider selling noted over the past three months. Still, Phase 3 success in a high-need cancer category is exactly the kind of news that can justify a premium in biotech.
My Take For You: Revolution just delivered the type of Phase 3 result that can reshape a biotech story. The valuation is high, but the clinical milestone is real.
My Verdict: Buy this. The risk is that the stock has already priced in too much success before approval, launch, and reimbursement are proven.
Trivia: When Charles Dow created the Dow Jones Industrial Average in 1896, it was a simple snapshot of American industry. How many companies made up the original index?
Movers and Shakers
Taylor Morrison Home [TMHC]: Premarket Move: +22%
Taylor Morrison is soaring after Berkshire Hathaway agreed to buy the homebuilder for $72.50 per share in cash, valuing the deal at about $8.5 billion including debt. That price is a 24% premium to Friday’s close and marks Greg Abel’s first major deal as Berkshire CEO.
This is not just a housing trade anymore. It is an acquisition story with a clean cash bid from one of the most credible buyers in the market.
My Take: Hold for the deal close. The easy money is mostly made, but there is no reason to sell aggressively unless the spread gets too tight.
Oculis Holding [OCS]: Premarket Move: -35%
Oculis is getting crushed after OCS-01 failed to hit the primary endpoint in both Phase 3 DIAMOND trials for diabetic macular edema. The drug did reduce retinal thickness, but it did not translate into better visual acuity, which is the result the market needed.
The company will not file for FDA approval in this indication and is shifting resources toward optic neuropathy and dry eye programs.
My Take: Stay away. This is a failed late-stage catalyst, and the stock needs a new lead story before it becomes buyable again.
Wise Group [WSE]: Premarket Move: -16%
Wise is plunging after confirming it is cooperating with Belgian prosecutors following reports that its platform was used in money-laundering activity. The company says law-enforcement requests are routine and do not prove wrongdoing, but that will not calm the market today.
For a fintech built on trust, compliance headlines hit hard. Wise already spent £131 million on compliance-related capabilities in the six months to September, which shows this is a major operating priority, not a side issue.
My Take: Do not buy this dip yet. Wise needs to prove this stays contained before investors should step back in.
Energy People Want (Sponsored)
Here's a shocking turn - Big Oil is lining up behind a new kind of clean energy in a BIG way. And they're not doing it just to pander to environmentalists.
Thanks to a breakthrough discovery, it turns out this new energy source is virtually limitless. It's found right here in America, beneath our feet.
And the oil companies are in a perfect position to extract it. We launched a 2,125-mile scouting mission to get the details.
Get the full story here - you won’t hear this anywhere else, but I believe this could make some people obscenely rich.
Everything Else
🚀 SpaceX is eyeing a $1.5 trillion IPO that would be 58X bigger than any offering in history and apparently you do not have to wait for Wall Street to get a piece of it.
💻 Nvidia’s new chip will power fresh Windows laptops from Dell and HP, because the AI PC race needed another obvious heavyweight.
🚩 Japan’s prime minister sent a bond-market warning with budget remarks, which is not ideal when investors are already jumpy.
🏭 China’s private factory survey beat forecasts in May, giving the economy a manufacturing bright spot despite softer official data.
📺 LG Electronics shares jumped 28%, because apparently investors found something they really liked in the latest update.
🚀 Blue Origin faces months of delays after its rocket explosion damaged the launch pad, which is a very expensive version of “try again later.”
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
